Tag: Loncastuximab tesirine-lpyl

Home / Loncastuximab tesirine-lpyl

Categories

The FDA has granted loncastuximab tesirine-lpyl accelerated approval for large B-cell lymphoma

August 2021: The FDA granted loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, accelerated approval for adult patients with relapsed...
loncastuximab-tesirine-lpyl

Scan the code